GP-21

GP-21 is a drug candidate series currently in the discovery or preclinical development stage, developed by the Swiss biotechnology company **GliaPharm**. The program is specifically targeting **Alzheimer's disease** and **schizophrenia**. GP-21 is part of GliaPharm's therapeutic pipeline that utilizes their proprietary **GliaX** platform, which focuses on modulating astrocyte metabolism. The core scientific approach involves enhancing brain energetics by targeting metabolic pathways in astrocytes to increase the energy available to the brain, addressing the metabolic deficiencies (such as glucose hypometabolism) frequently associated with neurodegenerative and psychiatric disorders.